iVeena Delivery Systems Announces Positive End-of-Phase 1 FDA Meeting for IVMED-85

SALT LAKE CITY--(BUSINESS WIRE)--iVeena Delivery Systems, Inc., “iVeena” a clinical-stage ophthalmic pharmaceutical company developing innovative therapies for eye diseases, today announced a successful End-of-Phase 1 Type B meeting with the U.S. Food and Drug Administration (FDA) for IVMED-85, an investigational, non-atropine eye drop being developed for the treatment of pediatric myopia. The meeting followed the recently announced successful completion of iVeena's Phase 1 clinical study evalu